Omeros (NASDAQ:OMER – Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, November 13th.
Omeros Price Performance
Shares of OMER opened at $4.29 on Tuesday. Omeros has a 1 year low of $1.17 and a 1 year high of $5.68. The company has a 50 day simple moving average of $4.01 and a two-hundred day simple moving average of $4.04. The firm has a market cap of $248.59 million, a P/E ratio of -1.83 and a beta of 1.47.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Friday, August 16th.
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Stories
- Five stocks we like better than Omeros
- How to Invest in Blue Chip Stocks
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- What is a Death Cross in Stocks?
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- These 3 Active ETFs Beat the S&P 500 Over the Last Five Years
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
